LOXL1 and cancer: Another LOXL inhibitor to show early promise in cancer treatment was the anti-LOXL2 monoclonal mouse antibody AB0023, which was effective in reducing intratumoral collagen density in vivo in a murine model of pancreatic cancer [157].